FDA Clears Viridian's Tepezza Rival for Thyroid Eye Disease

Viridian may have edge over Amgen in eye drug showdown, analysts argue

The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.

FDA clears Viridian's Tepezza rival for thyroid eye disease

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

FDA approves first treatment of thyroid eye disease

Red and bulging eyes are symptoms of thyroid eye disease. Image: Antonio/stock.adbe.com.The FDA has announced the approval of the first treatment for thyroid eye disease (TED) with the approval of veligrotug-vvze (Lumvoa; Viridian). According to an article in the American Journal of Managed Care (AJMC), the treatment can be used to address the autoimmune disease that causes inflammation and tissue remodeling. TED is a rare disorder that primaril…

Viridian wins FDA approval for Lumvoa for thyroid eye disease

Company secures first commercial product with data for active and chronic TED